Background
==========

The relationship between chronic psychological stress and reduced health is well established \[[@B1]\], with psychological stress having been shown to increase susceptibility to a wide range of diseases including anxiety, depression, diabetes, and obesity \[[@B2]-[@B4]\]. Even the "stress" of short-term sleep loss has significant implications for long-term health and well-being due to adverse systemic health effects including suppressed immune function, abdominal obesity, insomnia, depression, and generalized fatigue \[[@B5],[@B6]\].

Interventions for stress and anxiety range from nutritional support to the use of antidepressant medications such as benzodiazepines and selective serotonin reuptake inhibitors \[[@B7],[@B8]\]. A United States Patent (No. 6,582,735) has been granted for the use of an extract of *Magnolia officinalis* bark for stress related conditions involving elevated cortisol, such as control of body weight, sleep disturbances and restlessness \[[@B9]\].

Extracts of *Magnolia officinalis* bark and its active constituent, honokiol, have been studied in animal models with comparable anxiolytic activity to diazepam (a benzodiazepine anxiolytic used to treat anxiety), but without associated side effects such as sedation \[[@B10]-[@B13]\]. Berberine, a constituent of the *Phellodendron* extract, has also demonstrated a significant anxiolytic effect in rodent stress studies, including the elevated plus maze test and the forced swim test \[[@B14],[@B15]\]. The combination of magnolia plus phellodendron appears to be even more effective in controlling stress/anxiety compared to either herb used separately \[[@B16]-[@B19]\].

The subject of this study, Relora® (Next Pharmaceuticals, Inc, Salinas, CA), is a proprietary dietary supplement formulation consisting of a blend of extracts of *Magnolia officinalis* bark and *Phellodendron amurense* bark standardized to honokiol and berberine, respectively. In previous studies, Relora has demonstrated efficacy for reducing stress and anxiety in animals \[[@B18],[@B19]\] and enhancing feelings of well-being in human subjects \[[@B20],[@B21]\]. One study also measured the effects of Relora on salivary cortisol, finding benefits in reducing cortisol and increasing dehydroandrostenedione (DHEA) levels in stressed subjects \[[@B20]\].

In this study, we report the effects of using the Relora combination of magnolia bark and phellodendron bark on salivary cortisol and psychological well-being of healthy subjects under moderate levels of perceived psychological stress. The current study employed a well-validated psychological assessment known as the Profile of Mood States (POMS) to assess mood state. A key objective of the study was to explore how 4 weeks of magnolia/phellodendron supplementation (Relora versus a placebo) affected cortisol, various moods, and overall stress levels under conditions of moderate psychological stress.

Methods
=======

Dietary supplement
------------------

Relora® is a proprietary blend of a patented extract of the bark of *Magnolia officinalis* and an extract of the bark of *Phellodendron amurense* (US Patent Nos. 6,582,735 and 6,814,987). The product is standardized to "not less than 1.5% honokiol and 0.1% berberine." Subjects ingested 500 mg/day at breakfast (250 mg) and dinner (250 mg) in white opaque capsules or a look-alike placebo that was identical in size, shape and color.

Study design
------------

This study was done in accordance with the Helsinki Declaration, as revised in 1983, for clinical research involving humans and all procedures, measurements, and informed consent processes were reviewed and approved by an external third-party review board (Aspire IRB; Santee, CA).

Subjects signed informed consent documents after the study details were explained. The study used a randomized placebo-controlled, double-blind design. Subjects were randomly assigned, through a random number generator, to either 500 mg/day containing supplement (250 mg of Relora®, consumed at breakfast and dinner) or a look-alike Placebo (250 mg of rice flour); bottles were labeled only with a pre-assigned random code. Subjects self-administered the allotted capsule twice daily in the morning with breakfast and in the evening with dinner for 4 weeks. Subjects were contacted weekly to remind them to take their capsules daily. Empty bottles were returned after the study for a count of any unused capsules (an indicator of missed doses). Compliance with these instructions was high (data not shown).

We screened 60 subjects for moderate levels of psychological stress, with 56 subjects completing the study. Sixty (60) subjects were randomized to receive Supplement (30 subjects) or look-alike Placebo (30 subjects) for 4 weeks. The 4-week duration was selected as more representative of persistent changes in mood state that may result from superior hormone balance, as opposed to short-term changes in emotions that may be more closely linked with stressors of daily living.

At Baseline (week 0) and Post-supplementation (week 4), we assessed body weight and body fat percentage (Tanita BDF-300A bioelectrical impedance analyzer), overall stress (Yale Stress Survey), psychological mood state (Profile of Mood States Survey) and salivary cortisol. Mood State (Vigor, Depression, Anger, Confusion, Fatigue, and Anxiety) was assessed using the validated Profile of Mood States (POMS) survey \[[@B22],[@B23]\]. Cortisol exposure was assessed in pooled saliva samples collected at three time points during each collection day (morning, afternoon, and evening). The morning sample was collected upon waking at approximately 6am; the afternoon sample at approximately 2pm; and the evening sample immediately before bed at approximately 10pm to represent as much of a total daily "cortisol exposure" for each subject as possible. Cortisol circadian rhythm data will be reported elsewhere. Saliva samples were analyzed for free cortisol by enzyme immunoassay (EIA; Salimetrics, State College, PA, USA).

Fifty-six subjects (35 men & 21 women, age 28±11 years) completed the study, with two women in each group lost to follow up (did not return final surveys or saliva samples).

Mood assessment
---------------

We employed the Profile Of Mood States (POMS) questionnaire, to measure 6 primary psychological factors (tension, depression, anger, fatigue, vigor or confusion), plus the combined "global mood state" as an indication of subjective well-being. The POMS methodology has been used in nearly 3,000 studies and its validity is well established. The POMS profile uses 65 adjective-based intensity scales scored on a 0--4 hedonic scale (0 = not at all, 4 = extremely). The 65 adjective responses are categorized into the six mood factors (tension, depression, anger, fatigue, vigor or confusion), tabulated, scored and analyzed. The output of the POMS questionnaire is an assessment of the positive and negative moods of each subject at baseline and 4-weeks.

Data management and analysis
----------------------------

All questionnaires were completed at a central location and transcribed to a central database. Subjects that did not complete the questionnaires or submitted incomplete questionnaires were dropped from the study and not included in the study analysis (four subjects -- two females from each group). Data was identified by subject number and examined for accuracy and completeness. Tabulated data was analyzed with JMP 8.0 (SAS Institute) using standard parametric paired t-tests and significance was assessed with a two-tailed alpha level set at 0.05.

Results
=======

Over the course of the 4-week supplementation period, there were no adverse events or side effects reported. There were no significant changes in body weight or body fat percentage.

At week 4, salivary cortisol exposure was significantly (p\<0.05) lower (−18%) in the Relora group (Figure  [1](#F1){ref-type="fig"}).

![**Salivary Cortisol (ug/ml).** Salivary cortisol was 18% lower (p\<0.05) in the Relora group compared to Placebo at Week 4 (0.525[+]{.ul}0.190 to 0.642[+]{.ul}0.353).](1550-2783-10-37-1){#F1}

Significantly better (p\<0.05) mood state indices were observed in the Relora group for Overall Stress (−11%) and Global Mood State (−11%) compared to Placebo (Figure  [2](#F2){ref-type="fig"}). Mood State subscales (Figure  [3](#F3){ref-type="fig"}) were significantly better (p\<0.05) in the Relora group compared to Placebo at week 4; Tension (−13%), Depression (−20%), Anger (−42%), Fatigue (−31%), Confusion (−27%), and Vigor (+18%).

![**Global Mood State (POMS) and Overall Stress (Yale Stress Survey).** Global Mood State was 11% better (p\<0.05) in the Relora group compared to Placebo (118[+]{.ul}18 to 133[+]{.ul}30) -- lower score is a "better" Global Mood State (POMS). Overall Stress (Yale Stress Survey) was 11% lower (p\<0.05) in the Relora group compared to Placebo (30.2[+]{.ul}5.2 to 33.9[+]{.ul}7.4). The global mood state was calculated based on scoring (0-4 with 0 = not at all, 2 = moderately and 4 = extremely) answers to 58 of the 65 adjectives of the POMS (a lower number is a "better" global mood state). Global Mood State is the combined score of the 6 subscales of the POMS (McNair et al., \[[@B9]\]).](1550-2783-10-37-2){#F2}

![**Profile of Mood States (POMS).** Numerical scores for each of the 6 subscales of the POMS (McNair et al., \[[@B9]\]). The Relora group showed significantly improved mood state parameters compared to Placebo at Week 4 (\* = p\<0,05).](1550-2783-10-37-3){#F3}

Discussion
==========

Antidepressant drugs are the most commonly prescribed class of medications in the United States and are used by athletes and non-athletes alike \[[@B24]\]. More than 10% of the American population is taking one or more antidepressant drugs, which represents 27 million individuals taking more than 120 million prescriptions and spending over \$80 billion per year. According to a recent survey \[[@B25]\], large numbers of Americans feel an antidepressant drug would be helpful for; dealing with day-to-day stresses (83%); making things easier in relations with family and friends (76%); and helping people feel better about themselves (68%). However, because antidepressant drugs carry the United States Food and Drug Administration's most stringent "black box" warning (associated with serious life-threatening adverse effects), there is need for safe and effective natural approaches to reducing stress and anxiety.

In addition to a balanced diet, regular physical activity, and various stress management techniques, certain dietary supplements may be effective in naturally maintaining the normal balance between stress, cortisol, and emotional well-being. For example, there are numerous commercial examples of general-purpose "relaxation" and "calming" teas based on traditional herbal blends such as chamomile, fennel, lemon balm and others, while magnolia and phellodendron bark extracts have been specifically demonstrated as natural anxiolytic agents, \[[@B7]-[@B21],[@B26]\]. As such, appropriate dietary supplements may be a safe and effective natural adjunct to diet/exercise/stress management techniques to bring stress response and cortisol levels back to within normal ranges in individuals suffering from chronic stress or in athletes suffering from overtraining syndrome.

Magnolia bark *(Magnolia officinalis)* and Phellodendron bark (*Phellodendron amurense*) are traditional herbal medicines used since 100A.D. for treating "stagnation of Qi" in Chinese medicine \[[@B7],[@B8],[@B17]\], which is analogous to what we view in Western medicine as reduced psychological vigor or burnout. Magnolia bark extracts are rich in the phenolic compound, honokiol \[[@B12]\], while Phellodendron bark extracts are rich in berberine \[[@B14],[@B15]\] -- each of which contributes to the primary anti-stress, anti-anxiety, and cortisol-lowering effects of the plants \[[@B9]-[@B19],[@B26]\]. Research has shown magnolia and phellodendron extracts and their primary bioactives (honokiol and berberine) to possess powerful "mental acuity" benefits \[[@B10],[@B11],[@B16]\] via their actions in modulating the activity of various neurotransmitters and related enzymes in the brain, including brain-derived neurotrophic factor, acetylcholine, choline acetyltransferase, and acetylcholinesterase.

Numerous animal studies have demonstrated that honokiol and berberine act as anxiolytic agents \[[@B9]-[@B19],[@B26]\]. When compared to pharmaceutical agents such as Valium (diazepam), honokiol and berberine appear to be as effective in their anti-anxiety activity yet not nearly as powerful in their sedative ability \[[@B9],[@B12],[@B13]\]. These results have been demonstrated in numerous animal studies and suggest that Relora, which is standardized to both honokiol (from magnolia bark) and berberine (from phellodendron), is an effective natural approach for controlling the detrimental effects of everyday stressors, without the tranquilizing side effects of pharmaceutical agents \[[@B14]-[@B19],[@B26]\]. Previous human studies on Relora have shown similar anti-stress and anxiolytic benefits in moderately stressed subjects \[[@B20],[@B21]\]. The results reported in this study expand on previous findings of simple "relaxation" benefits of Relora to demonstrate specific effects on psychological mood state parameters in moderately-stressed subjects, including benefits for Global Mood State (analogous to an assessment of overall well-being), Tension, Depression, Fatigue, and Vigor (the opposite psychological state from "Burnout"). The magnitude of benefit in stress hormone (cortisol) reduction (18%) and mood state improvement (11%-42%) is meaningful from the perspective of optimal mental and physical performance. For example, the 18% higher Vigor or the 20% lower Depression score observed in the Relora group, could reasonably be associated with subjects reporting "feeling good" (in the case on our moderately-stressed subjects) or "performing well" (in the case of over-stressed or over-trained athletes, which should be the subject of future studies).

Although our study was not conducted in competitive athletes, a number of our moderately stressed healthy subjects were recreational runners and cyclists who commented about feeling more "balanced" in their workouts when their stress levels were balanced. This is a logical individual perception based on a number of studies in elite-level and recreational athletes that have found a direct relationship between overall stress (physical training and psychological stress) and athletic performance, including both mental and physical performance parameters \[[@B27]-[@B31]\]. Competitive athletes tend to be characterized by an elevated Vigor score and lower Fatigue score compared to non-athletes \[[@B27]\]. However, in many intervention studies of athletes, a dose--response exists between training stress and mood state \[[@B28],[@B29]\], so as overall physical "training stress" is elevated beyond a certain tipping point, psychological mood state becomes depressed. In addition, low Vigor scores and overall reduced psychological mood state have been identified as predictors of future athletic injury \[[@B30]\]. The most dramatic changes in psychological mood state are logically the result of intensified periods of training (e.g. increased training intensity and/or duration), which can be modulated positively or negatively by psychological stress (e.g. exams), competitive anxiety, social support network, sleep patterns, and recovery methods \[[@B27]-[@B31]\]. Based on the magnitude of the positive changes in cortisol levels and mood state parameters, we would recommend further athlete-specific studies to gauge the possible mental/physical performance benefits of Relora in enhancing post-exercise recovery and preventing over-training syndrome in competitive athletes.

Results from the current study indicate that daily supplementation with a combination of magnolia bark and phellodendron bark (Relora) reduces cortisol exposure and perceived stress, while improving a variety of mood state parameters. Compared to the Placebo group, salivary cortisol exposure was significantly lower (−18%) in the Relora group, while mood state parameters were significantly and meaningfully higher, including an 11% superior Global Mood State and 18% higher Vigor, with 13% lower Tension and 20% lower Depression indices. These results indicate that daily supplementation with a combination of Magnolia and Phellodendron (Relora) is an effective natural approach to the detrimental health effects of chronic stress.

Conclusions
===========

The present study indicates a significant "anti-stress" benefit of magnolia/phellodendron bark (Relora) supplementation in moderately stressed non-athletes, and suggests a possible benefit for athletes to recover from "training stress" induced by the physical and psychological demands of competition and training. Future studies should examine the potential benefits of Relora in helping athletes to enhance post-exercise recovery and possibly to help prevent overtraining syndrome.
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